Novo Nordisk's High Risk/Reward Proposition: 129% Rally Or 65% Drop?
1. Novo Nordisk enters final phase of Adhishthana Cycle; potential transformation ahead. 2. Weekly charts suggest bullish Nirvana, but monthly charts indicate imminent correction. 3. Weekly chart shows 88.5% alignment; monthly chart aligns only 60-65%. 4. Phase 18 targets suggest a rise of nearly 129% above current levels. 5. Conflicting signals create a high-risk, high-reward scenario for investors.